Use of imatinib to treat liver disorders and viral infections
View Patent ↗The present invention relates to the use of imatinib for treating viral liver diseases and in particular for viral hepatitis. The invention provides the use of imatinib for inhibiting replication, transmission or both of hepatitis viruses. The invention further relates to the use of imatinib for inhibiting replication, transmission or both of other viruses including herpes virus, poxvirus, influenza virus, para influenza virus, respiratory syncytial virus, rhinovirus, yellow fever virus, west nile virus, and encephalitis virus.
1. A method for treating a patient having a liver disorder, which comprises:
diagnosing whether the patient is infected with a hepatitis virus, wherein the patient is treated with imatinib based on positive evidence from a diagnostic test confirming that the patient is infected with a hepatitis virus;
administering to the virus-infected patient a therapeutically effective amount of imatinib or a pharmaceutically acceptable salt thereof to return the liver function of the patient to about normal level so as to treat the patient; and
monitoring the effect of the administering step at one or more times thereafter.
2. The method according to claim 1 , wherein the imatinib salt is imatinib mesylate.
3. The method according to claim 1 , wherein the patient is an animal.
4. The method according to claim 3 , wherein the animal is a mammal.
5. The method according to claim 1 , wherein the patient is a human.
6. The method according to claim 1 , wherein the virus is HCV, HAV, HBV, HDV or HEV.
7. The method according to claim 1 , wherein the virus is a non-A non-E (NANE) hepatitis virus.
8. A method for treating a patient infected with a hepatitis virus, which comprises administering to the patient a therapeutically effective amount of imatinib or a pharmaceutically acceptable salt thereof based on positive evidence from a diagnostic test confirming that the patient is infected with a hepatitis virus to return the liver function of the patient to about normal level so as to treat the patient.
9. The method according to claim 8 , wherein the virus is HCV, HAV, HBV, HDV, or HEV.
10. The method according to claim 8 , wherein the virus is a non-A non-E (NANE) hepatitis virus.
11. The method of claim 1 , wherein the diagnostic test is an antibody test for HCV.
12. A method for treating a patient having a liver disorder, which comprises:
diagnosing whether the patient is infected with a hepatitis virus, wherein the patient is treated with imatinib based on positive evidence from a diagnostic test confirming that the patient is infected with a hepatitis virus; administering to the virus-infected patient a therapeutically effective amount of imatinib or a pharmaceutically acceptable salt thereof to return the liver function of the patient to about normal level so as to treat the patient; and
monitoring the effect of the administering step at one or more times thereafter, and
which further comprises the co-administration of an interferon.
13. The method according to claim 12 , wherein the interferon is selected from a group consisting of: interferon alpha-2a, interferon alpha-2b, and pegylated derivatives thereof.
14. The method according to claim 12 , wherein the imatinib salt is imatinib mesylate.
15. The method according to claim 14 , wherein the amount of imatinib mesylate is between 100 mg/day and 1000 mg/day.
16. The method according to claim 14 , wherein the amount of imatinib mesylate is between 400 mg/day and 600 mg/day.
17. The method according to claim 14 , wherein the amount of imatinib mesylate is 400 mg/day.
18. The method according to claim 14 , wherein the amount of imatinib mesylate is between 260 mg/m 2 /day and 360 mg/m 2 /day.
19. A method for treating a patient infected with a hepatitis virus, which comprises administering to the patient a therapeutically effective amount of imatinib or a pharmaceutically acceptable salt thereof based on positive evidence from a diagnostic test confirming that the patient is infected with a hepatitis virus to return the liver function of the patient to about normal level so as to treat the patient, and which further comprises the co-administration of an interferon selected from a group consisting of: interferon alpha-2a, interferon alpha-2b, and pegylated derivatives thereof.
20. The method according to claim 19 , wherein the imatinib salt is imatinib mesylate.
21. The method according to claim 20 , wherein the amount of imatinib mesylate is between 100 mg/day and 1000 mg/day.
22. A method for treating a patient having a liver disorder, which comprises:
diagnosing whether the patient is infected with a hepatitis virus, wherein the patient is treated with imatinib based on positive evidence from a diagnostic test confirming that the patient is infected with a hepatitis virus;
administering to the virus-infected patient a therapeutically effective amount of imatinib or a pharmaceutically acceptable salt thereof to return the liver function of the patient to about normal level so as to treat the patient; and
monitoring the effect of the administering step at one or more times thereafter, and wherein,
for the time before said administering and during said administering, the patient is diagnosed with a liver disorder selected from the group consisting of hepatitis C virus infections.
23. The method of claim 22 wherein during said method, the patient is tested with one or more diagnostic tests selected from the group consisting of a) one or more tests to determine if the patient is infected with hepatitis C virus and b) one or more liver enzyme tests.